Reaction
Aortic Valve Replacement reporting signals
As of the last recalculation, Aortic Valve Replacement appears in 1,222 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is TAFAMIDIS (PRR 24.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tafamidis | 17 | 24.9 | 25.0 |
| Ranolazine | 14 | 23.1 | 23.1 |
| Bosentan | 33 | 11.4 | 11.4 |
| Alirocumab | 12 | 8.2 | 8.2 |
| Abiraterone | 5 | 6.3 | 6.3 |
| Patiromer | 5 | 6.2 | 6.2 |
| Nintedanib | 11 | 6.0 | 6.0 |
| Risankizumab-Rzaa | 28 | 5.9 | 5.9 |
| Dofetilide | 3 | 4.9 | 4.9 |
| Sevelamer Carbonate | 3 | 4.5 | 4.5 |
| Ambrisentan | 31 | 4.3 | 4.3 |
| Evolocumab | 35 | 3.8 | 3.8 |
| Cinacalcet Hydrochloride | 7 | 2.6 | 2.6 |
| Droxidopa | 3 | 2.4 | 2.4 |